Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

from TheBrief.Health · host TheBrief.Health

Large real-world study found apixaban, edoxaban, and rivaroxaban offer similar dementia protection in atrial fibrillation, allowing clinicians to prioritize safety, adherence, and patient-specific factors.

Episode metadata supplied by the publisher feed · Published Jun 25, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Direct Oral Anticoagulants and Dementia Risk in Nonvalvular Atrial Fibrillation: Evidence to Guide Clinical Selection

0:00 1:40

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on June 25, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!